Mayne Pharma Group
MYX.AXMayne Pharma Group is an Australian specialty pharmaceutical company with a dual focus on developing novel drug delivery technologies and commercializing a portfolio of branded and generic products. The company has built a substantial US commercial platform through acquisitions and leverages its in-house development and manufacturing capabilities. Its strategic direction centers on expanding its women's health franchise, optimizing its commercial portfolio, and advancing its pipeline of complex generic and 505(b)(2) products.
MYX.AX · Stock Price
Historical price data
AI Company Overview
Mayne Pharma Group is an Australian specialty pharmaceutical company with a dual focus on developing novel drug delivery technologies and commercializing a portfolio of branded and generic products. The company has built a substantial US commercial platform through acquisitions and leverages its in-house development and manufacturing capabilities. Its strategic direction centers on expanding its women's health franchise, optimizing its commercial portfolio, and advancing its pipeline of complex generic and 505(b)(2) products.
Technology Platform
Specialized in developing and manufacturing complex dosage forms, including modified-release oral solids, topical/transdermal systems, and sterile injectables, with a strategic focus on the 505(b)(2) regulatory pathway for novel formulations.
Pipeline
12| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Sporanox + Lozanoc | Neutropenia | Approved | |
| Halobetasol Topical Foam | Plaque Psoriasis | Approved | |
| Doxycycline Hyclate Delayed-Release 200 mg | Gonorrhea | Approved | |
| Slow release oral morphine (SROM) + Methadone | Opioid-Related Disorders | Phase 3 | |
| Permethrin Cream, 5% + Elimite | Scabies | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
Mayne Pharma competes with large multinational pharma and generic companies (e.g., Pfizer, Teva, Viatris) in the US, and domestic players in Australia. Its differentiation lies in its focus on complex, hard-to-make dosage forms, an integrated development-to-commercialization model, and a targeted portfolio in women's health and dermatology.